HomeNewsBeritaBusinessLifestyleOpinionWorldSportsPropertyEducationCarzillaGalleryVideosAccelerator

GSK to stop selling blood cancer drug Blenrep in US

-

The marketing of Blenrep continues in 17 other countries mostly in the EU.

0
Shares
Total Views: 1
Free Malaysia Today
Oncology is a key area of focus for GSK as a standalone prescription medicine and vaccine business. (File pic)

LONDON:
GSK will stop selling its blood cancer drug Blenrep in the US, it said on Tuesday, in another setback for the British drug-maker’s oncology business.

The company had said this month that Blenrep had failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the US Food and Drug Administration (FDA).

On Tuesday GSK said it has begun the process to withdraw Blenrep’s marketing authorisation in the country but would continue trial programmes for the drug, adding that some patients will have the option to enrol for continued access to the treatment.

The drugmaker’s shares were down 0.2% at 1.45pm.

“We will continue the Dreamm clinical trial programme and work with the US FDA on a path forward for this important treatment option for patients with multiple myeloma,” GSK chief medical officer Sabine Luik said in a statement.

Marketing of Blenrep continues in the 17 other countries – mostly in the EU – where it has been approved, a GSK official said, but the US move will raise doubts about the drug’s future.

The company is still discussing the latest clinical data with EU health authorities, the official said.

The drug was given speedy approval by the FDA in 2020 and approved for patients with relapsed or refractory multiple myeloma who received at least four previous therapies.

Last year, the drug achieved £89 million (US$105 million) in global sales, about two-thirds of which were from the US.

In an indication of the high hopes GSK once had for the drug, the company last year forecast peak sales for Blenrep of more than £3 billion (US$3.56 billion).

Oncology is a key area of focus for GSK as a standalone prescription medicine and vaccine business. However, the company suffered another setback this month after it had to limit the use of its ovarian cancer drug Zejula in the US.

Blenrep belongs to a category of treatments called antibody drug conjugates, which are engineered antibodies that bind to tumour cells and then release cell-killing chemicals.

Stay current - Follow FMT on WhatsApp, Google news and Telegram

Subscribe to our newsletter and get news delivered to your mailbox.